{
    "nctId": "NCT03176888",
    "briefTitle": "Health Benefits of HIT for Breast Cancer Patients",
    "officialTitle": "The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Change in maximal aerobic capacity (VO2max)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Recent diagnosis of biopsy-proven primary invasive breast cancer\n2. Pre- or post-menopausal women\n3. World Health Organisation Performance status 0-2\n4. No distant metastasis\n5. On a treatment plan of:\n\n   1. surgery (breast conservation surgery or mastectomy with or without reconstruction, including axillary surgery)\n   2. Adjuvant treatment with hormonal therapy and/or radiotherapy\n   3. Adjuvant chemotherapy with or without anti-Her-2 therapy\n6. Can start the study within 1 week of diagnosis and prior to surgery\n7. Have surgery arranged within 1-4 weeks of diagnosis\n8. All receptor statuses are eligible\n\nExclusion Criteria:\n\n1. BMI \\> 35 kg\u00b7m-2\n2. Age \\< 35 y or \\> 60 y\n3. Men\n4. Verbal self-report of undertaking five or more structured exercise sessions per week, perceived as being moderate-to-vigorous intensity, and each session being \u2265 30 minutes in duration\n5. Contraindications to exercise as determined using the Physical Activity Readiness Questionnaire (PAR-Q)\n6. Any known significant cardiovascular (except controlled hypertension), pulmonary (except treated/controlled asthma) or metabolic disease (except hypercholesterolemia or type II diabetes)\n7. Auto-immune disease or exercise-limiting inflammatory arthritis\n8. Distant metastasis\n9. Secondary breast cancer or previous diagnosis of invasive cancer and treatment within last 5 years except\n\n   1. Localised basal cell carcinoma or squamous cell carcinoma of skin\n   2. In situ melanoma\n   3. Cervical intraepithelial neoplasia (CIN)\n10. Neoadjuvant chemotherapy",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT"
}